Moffett Cancer Center joins Dana-Farber Cancer Institute to help stop blood cancer

Tampa, Florida

"We are very happy to be part of the PROMISE study and join our colleagues at the Dana-Farber Cancer Institute to help find answers to cancers that have no early signs and symptoms

Multiple myeloma is not a common cancer, but it is the second most common blood cancer in the United States after non-Hodgkin's lymphoma

Brandon Blue, MD, an assistant member of Moffitt's Department of Hematology, said: "In the premalignant state, it is urgent to contact patients of all races and ethnicities as soon as possible to ideally prevent the incidence of active multiple myeloma

"This early detection of cancer has been evading, because stand up generous cancer funding to start this research.

In order to be eligible to participate in the PROMISE study, you must meet at least one of the following:

1. People between the ages of 40-75 who consider themselves black or African American; or

2. People between 40-75 years of age who have first-degree blood relatives (parents, siblings, or children) are diagnosed with any type of blood cancer, such as lymphoma, leukemia, multiple myeloma, monoclonal gamma disease of unknown significance, or negative Burning myeloma; or

3. People who are 18 years or older and have or have two or more relatives diagnosed with blood cancer can also participate

   
   

Eligible participants will receive a toolkit that they can take home to any Quest diagnostic center to collect a small sample for free

Shane said: "We hope that the people in Florida will sign a commitment to study to help us stop blood cancer